Recursion and Bayer to wind down fibrosis R&D pact after three years, refocusing on cancer
Recursion Pharmaceuticals and Bayer reworked a research pact to focus on oncology instead of fibrosis as the German drugmaking giant homes in on cancer under new CEO Bill Anderson.
Bayer became Recursion’s first Big Pharma partner when the two signed a five-year research deal in 2020 aiming to identify fibrosis therapies. Now, more than three years later, the two companies said Thursday they will wind down the fibrosis work that involved more than a dozen projects. Bayer has yet to exercise any licenses on lead series or development candidates from that fibrosis research, according to regulatory filings.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
